Publications

Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups.
Pharmacogenomics 2015 Jul 17;16(8):817-24. Epub 2015 Jun 17.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, PR China.

Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.
Clin J Pain 2015 Jan;31(1):21-9
*Department of Surgery, University of North Carolina, Chapel Hill §Wake Forest Baptist Medical Center, Winston-Salem, NC †Washington Hospital Center, Washington, DC ‡Crozer Chester Medical Center, Upland, PA.

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Breast Cancer Res Treat 2013 May 16;139(1):135-43. Epub 2013 Apr 16.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1-1M52, Baltimore, MD 21231, USA.



Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Pharmacogenomics 2012 Jan 23;13(1):113-21. Epub 2011 Nov 23.
University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599-7569, USA.





Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
J Clin Oncol 2006 Jun 1;24(16):2448-55. Epub 2006 May 1.
Westmead Institute for Cancer Research Westmead Millennium Institute, Department of Translational Oncology, Westmead, Australia.

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Clin Pharmacol Ther 2005 Jan;77(1):33-42
Westmead Institute for Cancer Research, Department of Nuclear Medicine, Westmead Hospital, University of Sydney, Camperdown, Australia.

Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.
PLoS One 2012 27;7(7):e41954. Epub 2012 Jul 27.
Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

OF